Literature DB >> 34262178

Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease.

Cameron S McAlpine1,2,3, Joseph Park4, Ana Griciuc4, Eunhee Kim4, Se Hoon Choi4, Yoshiko Iwamoto1, Máté G Kiss1, Kathleen A Christie5, Claudio Vinegoni1, Wolfram C Poller1,2, John E Mindur1, Christopher T Chan1, Shun He1, Henrike Janssen1, Lai Ping Wong6,7, Jeffrey Downey1, Sumnima Singh1, Atsushi Anzai1, Florian Kahles1, Mehdi Jorfi4, Paolo Fumene Feruglio8, Ruslan I Sadreyev6,9, Ralph Weissleder1, Benjamin P Kleinstiver5, Matthias Nahrendorf1, Rudolph E Tanzi10, Filip K Swirski11,12.   

Abstract

Communication within the glial cell ecosystem is essential for neuronal and brain health1-3. The influence of glial cells on the accumulation and clearance of β-amyloid (Aβ) and neurofibrillary tau in the brains of individuals with Alzheimer's disease (AD) is poorly understood, despite growing awareness that these are therapeutically important interactions4,5. Here we show, in humans and mice, that astrocyte-sourced interleukin-3 (IL-3) programs microglia to ameliorate the pathology of AD. Upon recognition of Aβ deposits, microglia increase their expression of IL-3Rα-the specific receptor for IL-3 (also known as CD123)-making them responsive to IL-3. Astrocytes constitutively produce IL-3, which elicits transcriptional, morphological, and functional programming of microglia to endow them with an acute immune response program, enhanced motility, and the capacity to cluster and clear aggregates of Aβ and tau. These changes restrict AD pathology and cognitive decline. Our findings identify IL-3 as a key mediator of astrocyte-microglia cross-talk and a node for therapeutic intervention in AD.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34262178      PMCID: PMC8934148          DOI: 10.1038/s41586-021-03734-6

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  60 in total

1.  Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome.

Authors:  Markus Britschgi; Kaspar Rufibach; Sarah L Bauer Huang; Christopher M Clark; Jeffrey A Kaye; Ge Li; Elaine R Peskind; Joseph F Quinn; Douglas R Galasko; Tony Wyss-Coray
Journal:  Mol Cell Proteomics       Date:  2011-07-08       Impact factor: 5.911

2.  Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.

Authors:  Ana Griciuc; Alberto Serrano-Pozo; Antonio R Parrado; Andrea N Lesinski; Caroline N Asselin; Kristina Mullin; Basavaraj Hooli; Se Hoon Choi; Bradley T Hyman; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-04-25       Impact factor: 17.173

3.  ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation.

Authors:  Laurent Yvan-Charvet; Tamara Pagler; Emmanuel L Gautier; Serine Avagyan; Read L Siry; Seongah Han; Carrie L Welch; Nan Wang; Gwendalyn J Randolph; Hans W Snoeck; Alan R Tall
Journal:  Science       Date:  2010-05-20       Impact factor: 47.728

4.  A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

Authors:  Hadas Keren-Shaul; Amit Spinrad; Assaf Weiner; Orit Matcovitch-Natan; Raz Dvir-Szternfeld; Tyler K Ulland; Eyal David; Kuti Baruch; David Lara-Astaiso; Beata Toth; Shalev Itzkovitz; Marco Colonna; Michal Schwartz; Ido Amit
Journal:  Cell       Date:  2017-06-08       Impact factor: 41.582

5.  TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.

Authors:  Ana Griciuc; Shaun Patel; Anthony N Federico; Se Hoon Choi; Brendan J Innes; Mary K Oram; Gea Cereghetti; Danielle McGinty; Anthony Anselmo; Ruslan I Sadreyev; Suzanne E Hickman; Joseph El Khoury; Marco Colonna; Rudolph E Tanzi
Journal:  Neuron       Date:  2019-07-10       Impact factor: 17.173

6.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.

Authors:  Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray
Journal:  Nat Med       Date:  2007-10-14       Impact factor: 53.440

Review 7.  Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.

Authors:  Yu Yamazaki; Na Zhao; Thomas R Caulfield; Chia-Chen Liu; Guojun Bu
Journal:  Nat Rev Neurol       Date:  2019-07-31       Impact factor: 44.711

8.  TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models.

Authors:  Taylor R Jay; Crystal M Miller; Paul J Cheng; Leah C Graham; Shane Bemiller; Margaret L Broihier; Guixiang Xu; Daniel Margevicius; J Colleen Karlo; Gregory L Sousa; Anne C Cotleur; Oleg Butovsky; Lynn Bekris; Susan M Staugaitis; James B Leverenz; Sanjay W Pimplikar; Gary E Landreth; Gareth R Howell; Richard M Ransohoff; Bruce T Lamb
Journal:  J Exp Med       Date:  2015-03-02       Impact factor: 14.307

9.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

Authors:  John G Doench; Nicolo Fusi; Meagan Sullender; Mudra Hegde; Emma W Vaimberg; Jennifer Listgarten; Katherine F Donovan; Ian Smith; Zuzana Tothova; Craig Wilen; Robert Orchard; Herbert W Virgin; David E Root
Journal:  Nat Biotechnol       Date:  2016-01-18       Impact factor: 54.908

10.  Direct intraventricular delivery of drugs to the rodent central nervous system.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  J Vis Exp       Date:  2013-05-12       Impact factor: 1.355

View more
  29 in total

1.  Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma.

Authors:  Milica A Margeta; Zhuoran Yin; Charlotte Madore; Kristen M Pitts; Sophia M Letcher; Jing Tang; Shuhong Jiang; Christian D Gauthier; Sebastian R Silveira; Caitlin M Schroeder; Eleonora M Lad; Alan D Proia; Rudolph E Tanzi; David M Holtzman; Susanne Krasemann; Dong Feng Chen; Oleg Butovsky
Journal:  Immunity       Date:  2022-08-16       Impact factor: 43.474

2.  Microglia-Mediated Aβ Propagation in Alzheimer's Disease.

Authors:  Luoman Yang; Shu Feng; Chongyun Wu; Luodan Yang
Journal:  Neurosci Bull       Date:  2022-06-21       Impact factor: 5.271

3.  Grafted human ESC-derived astroglia repair spinal cord injury via activation of host anti-inflammatory microglia in the lesion area.

Authors:  Jian Wang; Peng Jiang; Wenbin Deng; Yuhui Sun; Yaobo Liu
Journal:  Theranostics       Date:  2022-05-16       Impact factor: 11.600

4.  Astrocytic α2-Na+/K+ ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model.

Authors:  Carolyn N Mann; Shamulailatpam Shreedarshanee Devi; Corey T Kersting; Amber V Bleem; Celeste M Karch; David M Holtzman; Gilbert Gallardo
Journal:  Sci Transl Med       Date:  2022-02-16       Impact factor: 19.319

5.  Astrocytic IL-3 could help microglia protect against Alzheimer disease.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2021-09       Impact factor: 42.937

6.  Desferrioxamine Ameliorates Lipopolysaccharide-Induced Lipocalin-2 Upregulation via Autophagy Activation in Primary Astrocytes.

Authors:  Juntao Cui; Yu Yuan; Jun Wang; Ning Song; Junxia Xie
Journal:  Mol Neurobiol       Date:  2022-01-18       Impact factor: 5.590

Review 7.  Positron Emission Tomography in Animal Models of Tauopathies.

Authors:  Lei Cao; Yanyan Kong; Bin Ji; Yutong Ren; Yihui Guan; Ruiqing Ni
Journal:  Front Aging Neurosci       Date:  2022-01-10       Impact factor: 5.750

8.  A fragment of cell adhesion molecule L1 reduces amyloid-β plaques in a mouse model of Alzheimer's disease.

Authors:  Junkai Hu; Stanley Li Lin; Melitta Schachner
Journal:  Cell Death Dis       Date:  2022-01-10       Impact factor: 8.469

9.  MARCH3 negatively regulates IL-3-triggered inflammatory response by mediating K48-linked polyubiquitination and degradation of IL-3Rα.

Authors:  Lu Feng; Chen Li; Lin-Wen Zeng; Deng Gao; Yu-Hao Sun; Li Zhong; Heng Lin; Hong-Bing Shu; Shu Li
Journal:  Signal Transduct Target Ther       Date:  2022-01-24

Review 10.  Synapses, Microglia, and Lipids in Alzheimer's Disease.

Authors:  Patrick J Paasila; Jason A Aramideh; Greg T Sutherland; Manuel B Graeber
Journal:  Front Neurosci       Date:  2022-01-12       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.